Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DA-5221_01 vs. Concomitant R1 and R2 in Healthy Volunteers
NCT06616883Phase 1Not yet recruiting
- Sponsor
- Dong-A ST
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 and dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
DA5221-B2dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06616883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616883.